This article, written with co-authors Bruce H. Kobayashi, Joshua D. Wright, and Douglas H. Ginsburg, examines the economics of litigation and settlement of patent disputes arising from Paragraph IV Abbreviated New Drug Application (ANDA) filings under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) within the framework set out in Actavis.
SEP licensing in the United States: Understanding the impact on US business
US Business Survey On behalf of ACT | The App Association, consultants with Charles River Associates undertook a survey of US businesses that use technical...